GET DAILY SIGNALSTempest Therapeutics (TPST): Pipeline Evolution and Clinical Milestones on the Horizon
Key Takeaways
- Major upcoming catalysts: The pivotal Phase 3 trial for amezalpat in first-line liver cancer and the start of a Phase 2 study for TPST-1495 anchor Tempest's near-term clinical plans.
- Strategic positioning: A move into cell therapy, centered on the acquisition of Factor Bioscience's CAR-T programs, is reshaping the pipeline and extending cash runway into 2027.
- Industry tailwinds and headwinds: Orphan Drug and Fast Track designations for amezalpat bolster development prospects, yet clinical-stage biotech remains sensitive to financing conditions and regulatory timelines.
- Key macro sensitivity: Interest rates and investor appetite for pre-revenue biotech directly affect Tempest's capacity to raise capital and advance trials without heavy dilution.
- Analyst stance: Coverage remains limited, with a Moderate Buy rating and one published 12-month price target of $7.00, signaling measured optimism on the updated pipeline.
- Risks to watch: Dilution from recent raises, a lean balance sheet, and execution risk across multiple early programs could shift the outlook materially.
- For more context, explore Major News, Today's Price Move, Price Targets, and Earnings on dedicated pages.
- To round out analysis, consider Trending AI Robots for additional data-driven perspectives.
Tempest's Shifting Strategy and Competitive Landscape
Tempest Therapeutics operates as a clinical-stage biotechnology firm developing first-in-class oncology treatments. Its lead candidate, amezalpat (TPST-1120), functions as an oral small-molecule antagonist of PPARα, a target tied to tumor metabolism and immune suppression. Development focuses on combining it with standard immunotherapy for first-line hepatocellular carcinoma, the most common primary liver cancer.
The competitive stance has changed notably. The late-2025 acquisition of Factor Bioscience's cell therapy assets brought in CAR-T programs such as TPST-2003, moving beyond a narrow small-molecule focus while lengthening the cash runway. This introduces added execution demands, as the company balances a later-stage oncology asset with an early cell-therapy platform under constrained resources. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge near-term directional signals around TPST.
Regulatory support includes FDA Orphan Drug and Fast Track designations plus EMA orphan status for amezalpat, which facilitate dialogue and potential exclusivity. Still, as a pre-revenue entity, success hinges on trial outcomes and further financing or partnerships.
Near-Term Catalysts and Analyst Perspectives
Several events stand to influence sentiment. The next quarterly update, expected around November 9, 2026, should detail cash levels, trial timelines, and any business-development progress—critical disclosures for a firm with limited runway.
The pivotal Phase 3 trial for amezalpat in first-line HCC represents the most significant clinical step. Alignment with FDA, EMA, and Chinese regulators is already in place, and a Roche collaboration evaluating the candidate with atezolizumab and bevacizumab adds validation, though data are unlikely until later in the decade.
A Phase 2 study of TPST-1495 in familial adenomatous polyposis, funded by the National Cancer Institute, is slated for late 2026 or early 2027, providing a lower-cost incremental readout. Analyst views center on H.C. Wainwright's Joseph Pantginis, who raised the rating to Buy in January 2026 with an $11 target before trimming it to $7 in September 2026 due to dilution and delayed TPST-2003 timing. Consensus now sits at Moderate Buy with a $7.00 average target, underscoring both pipeline potential and execution risks.
Industry Dynamics and Macro Influences
Within oncology biotech, value accrues primarily from clinical data and regulatory events rather than near-term earnings. Interest rates remain a pivotal macro factor, as higher costs constrain capital access for pre-revenue names and directly affect Tempest's ability to fund Phase 3 work. Any sustained improvement in financial conditions could lift sentiment across speculative biotech stocks.
Regulatory support from existing Fast Track and Orphan designations reduces friction, while broader immuno-oncology trends favor differentiated mechanisms like PPARα antagonism. Geopolitical elements surface indirectly through clearance for a pivotal trial in China, expanding patient access yet adding operational layers. Cell-therapy adoption trends support the strategic pivot, even as larger rivals hold advantages in scaling manufacturing and commercialization—making partnerships and financing outcomes decisive.
2026 Outlook and Longer-Term Considerations
Looking ahead, Tempest's path centers on translating the repositioned pipeline into concrete clinical advances. The pivotal amezalpat program in first-line HCC stands as the dominant long-term driver, with potential to elevate the company's position if successful. Additional avenues include the externally funded TPST-1495 trial and a possible U.S. IND filing for TPST-2003.
Capital allocation, including any strategic-alternatives process or financing events, will set the development pace given the absence of revenue. Competitive pressures from larger oncology players and evolving cell-therapy technologies remain ongoing risks, while regulatory extensions or expedited pathways could provide upside. The $7.00 consensus target implies current valuation understates pipeline optionality, conditional on financing success and clinical delivery through 2026 and 2027.
Insights from Tickeron AI Tools
In my own review process, I have found Tickeron's AI Trend Prediction Engine helpful for layering quantitative signals onto fundamental work on names like TPST. The tool offers searchable forecasts, historical context, and alerts that can flag potential trend shifts over the coming weeks or months, serving as a useful complement when monitoring clinical-stage biotech volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for TPST turns negative, indicating new downward trend
TPST saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for TPST turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 44 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TPST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TPST entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
Following a +4.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where TPST advanced for three days, in 178 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TPST may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-5.897) is normal, around the industry mean (3.498). P/E Ratio (-0.103) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TPST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TPST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceuticals
Industry Biotechnology
Advertisement